phrykt

Perspective Therapeutics, Inc. (CATX): who owns it and who trades it

As of Nov 16, 2026, CATX insiders reported 5 open-market sales worth $1.3M and 7 purchases worth $128K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Lantheus Alpha Therapy, LLC (10% owner), with $1.1M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Perspective Therapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CATX

130 funds and institutions reported CATX shares worth $307M at the end of Q2 2026, about 79% of the company. The largest holder is BlackRock, Inc. with 8.3%.

Funds and institutions (13F) 79%Everyone else 21%

10 largest owners, by share of the company

BlackRock, Inc.8.3%
TCG Crossover Management, LLC6.9%
Commodore Capital LP5.6%
Avidity Partners Management LP5.5%
State Street Corp5.3%
Millennium Management LLC4.3%
Nantahala Capital Management, LLC4.1%
Vanguard Capital Management LLC3.9%
Affinity Asset Advisors, LLC3.7%
Citadel Advisors LLC3.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.9.49M8.33%$32.4M+78%
TCG Crossover Management, LLC7.92M6.95%$27MNo change
Commodore Capital LP6.34M5.56%$21.6MNo change
Avidity Partners Management LP6.30M5.53%$21.5M-48%
State Street Corp6.05M5.31%$20.6M+93%
Millennium Management LLC4.91M4.31%$16.7M+21%
Nantahala Capital Management, LLC4.65M4.08%$15.9M–
Vanguard Capital Management LLC4.44M3.89%$15.1M+1%
Affinity Asset Advisors, LLC4.21M3.70%$14.4M+33%
Citadel Advisors LLC3.81M3.34%$13M+7%
Spruce Street Capital LP3.69M3.24%$12.6M+41%
Balyasny Asset Management L.P.3.32M2.91%$11.3M+11%
Geode Capital Management, LLC2.46M2.16%$8.4M+39%
Morgan Stanley1.91M1.68%$6.5M-36%
Goldman Sachs Group Inc1.73M1.52%$5.9M+40%
Nicholson Wealth Management Group, LLC1.62M1.42%$5.5M+0%
Two Sigma Investments, LP1.56M1.37%$5.3M+55%
ADAR1 Capital Management, LLC1.21M1.06%$4.1M+61%
Vanguard Portfolio Management LLC1.09M0.95%$3.7M+45%
Dimensional Fund Advisors LP1.07M0.94%$3.7M+139%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CATX insiders reported $128K of open-market purchases and $1.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$128K
7 trades, 5 people
Sales, 12 months
$1.3M
5 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$1M$1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Frank MorichDirectorPurchase15,000$1.00$15KForm 4
Nov 12, 2026Lori A WoodsDirectorPurchase23,750$0.84$20KForm 4
Nov 12, 2026Robert F Williamson IIIDirectorPurchase18,609$0.84$15.6KForm 4
Nov 12, 2026Robert F Williamson IIIDirectorPurchase6,289$0.84$5.3KForm 4
Nov 12, 2026Markus PuhlmannChief Medical OfficerPurchase35,000$0.84$29.6KForm 4
Nov 11, 2026Markus PuhlmannChief Medical OfficerPurchase6,000$0.83$5KForm 4
Nov 11, 2026Johan M. SpoorCEOPurchase47,000$0.81$37.9KForm 4
Sep 4, 2026Lantheus Alpha Therapy, LLC +110% ownerSale167,149$3.15$527KForm 4
Sep 3, 2026Lantheus Alpha Therapy, LLC +110% ownerSale80,783$3.11$251KForm 4
Sep 2, 2026Lantheus Holdings, Inc. +110% ownerSale42,129$3.11$131KForm 4
Sep 1, 2026Lantheus Alpha Therapy, LLC10% ownerSale35,769$3.12$112KForm 4
Aug 31, 2026Lantheus Alpha Therapy, LLC10% ownerSale78,145$3.14$245KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Lantheus Alpha Therapy, LLC10% owner–$1.1MSep 4, 2026
Lantheus Holdings, Inc.10% owner–$131KSep 2, 2026
Johan M. SpoorChief Executive Officer, Director$37.9K–Nov 11, 2026
Markus PuhlmannChief Medical Officer$34.5K–Nov 12, 2026
Robert F Williamson IIIDirector$20.9K–Nov 12, 2026
Lori A WoodsDirector$20K–Nov 12, 2026
Frank MorichDirector$15K–Nov 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CATX short interest

Moderate short interest. 7.9% of CATX shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went down 29%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.97M CATX shares were sold short, 7.9% of the shares outstanding, down 46.2% from the report before. At the average daily volume of 3.63M shares, buying them all back would take about 2.5 trading days (days to cover).

Shares short, % of all shares

7.86%May 15Oct 3022.5%

Days to cover

2.5May 15Oct 3029.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.97M7.86%-46%3.63M2.5
Oct 15, 202616.68M14.61%+1%1.87M8.9
Sep 30, 202616.57M14.52%-27%3.00M5.5
Sep 15, 202622.81M19.98%-2%1.35M16.9
Aug 31, 202623.35M20.46%+1%987,92123.6
Aug 14, 202623.04M20.18%-2%1.26M18.2
Jul 31, 202623.47M20.60%+3%914,97025.6
Jul 15, 202622.78M20.00%+0%2.28M10.0
Jun 30, 202622.72M19.95%+67%3.12M7.3
Jun 15, 202613.63M11.97%+7%1.52M9.0
May 29, 202612.76M11.20%+1%1.13M11.3
May 15, 202612.62M11.07%-3%1.59M8.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Perspective Therapeutics company events

Perspective Therapeutics filed 25 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementAlso on November 9, 2026, the Company posted an updated corporate presentation to its website at www.perspectivetherapeutics.com. Filing
  2. Nov 6, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release and posted to its website a poster presentation announcing updated interim results from the Company’s Phase 1/2a clinical trial of [ 212 Pb]lapemelanotide zapixetar (VMT01) for the diagnosis and treatment of patients with unresectable or… Filing
  3. Nov 6, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing incremental data and analyses from the Company’s Phase 1/2a clinical trial of [ 212 Pb]Bamzireotide Navoxetan in patients with unresectable or metastatic somatostatin receptor type 2-expressing… Filing
  4. Oct 23, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype… Filing
  5. Oct 8, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous… Filing
  6. Oct 1, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  7. Sep 14, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release announcing a clinical collaboration and supply agreement with Merck. Filing
  8. Sep 8, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  9. Aug 10, 2026AnnouncementAlso on August 10, 2026, the Company posted an updated corporate presentation to its website at www.perspectivetherapeutics.com. Filing
  10. Aug 3, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  11. Jul 1, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  12. Jun 1, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  13. May 27, 2026VoteReported shareholder vote results. Filing
  14. May 22, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release announcing certain interim results from its ongoing clinical trials that are being presented at the 2026 American Society of Clinical Oncology Annual Meeting taking place May 29-June 2, 2026 in Chicago, Illinois. Filing
  15. May 11, 2026AnnouncementAlso on May 11, 2026, the Company posted an updated corporate presentation on its website at www.perspectivetherapeutics.com. Filing
  16. May 4, 2026AnnouncementThe Company posted the Presentation to its website. Filing
  17. Apr 20, 2026AnnouncementPerspective Therapeutics, Inc. posted to its website a poster regarding certain interim results from its Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors that… Filing
  18. Apr 1, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  19. Mar 16, 2026AnnouncementAlso on March 16, 2026, the Company posted an updated corporate presentation on its website at www.perspectivetherapeutics.com. Filing
  20. Feb 3, 2026AgreementPerspective Therapeutics, Inc. entered into an underwriting agreement with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein, in connection with its previously announced underwritten offering of 39,576,088 shares of the Company’s common stock, par… Filing
  21. Feb 2, 2026AnnouncementThe Company posted the Presentation to its website. Filing
  22. Jan 14, 2026AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing
  23. Jan 12, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release announcing certain business updates and strategic priorities for the Company. Filing
  24. Jan 9, 2026AnnouncementPerspective Therapeutics, Inc. issued a press release announcing certain updated interim data from its Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs) that are being presented at the… Filing
  25. Dec 1, 2025AnnouncementPerspective Therapeutics, Inc. updated its corporate presentation. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Perspective Therapeutics financials

Famous investors that hold CATX

5 of the 50 well-known investors we track reported holding CATX in their latest 13F filing. The largest position is Israel Englander's, worth $17M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20266.19M$17M0.0%+26%
Ken Griffin · Citadel AdvisorsQ3 20263.98M$10.9M0.0%+5%
Jim Simons · Renaissance TechnologiesQ3 2026221,633$609K0.0%+275%
Paul Tudor Jones · Tudor Investment CorpQ3 202633,714$92.7K0.0%+86%
Steve Cohen · Point72 Asset ManagementQ3 202621,260$58.5K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CATX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Commodore Capital LP13G/A5.5%
Nov 16, 2026Commodore Capital LP13G/A5.5%
Nov 12, 2026Lantheus Holdings, Inc.13D/A3.9%
Nov 12, 2026Lantheus Holdings, Inc.13D/A3.9%
Nov 10, 2026STATE STREET CORPORATION13G1.8%
Nov 10, 2026STATE STREET CORPORATION13G1.8%

Questions about Perspective Therapeutics, Inc. (CATX) stock

Who owns the most CATX stock?

The largest reported owner of Perspective Therapeutics, Inc. (CATX) is BlackRock, Inc., with 8.3% of the company. In total, 130 funds and institutions reported holding CATX at the end of Q2 2026, together about 79% of the shares. See the largest owners.

Are CATX insiders buying or selling?

In the last 12 months, CATX insiders reported 7 open-market purchases worth $128K and 5 sales worth $1.3M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in CATX?

As of Oct 30, 2026, 8.97M CATX shares were sold short, 7.9% of the shares outstanding, down 46.2% from the report before. At the average daily volume of 3.63M shares, buying them all back would take about 2.5 trading days (days to cover). See the history.

Which famous investors hold CATX?

5 of the 50 well-known investors we track reported CATX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $17M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.